α-Synuclein in Lewy bodies
1997/08/28 by Maria Grazia Spillantini, Marie Luise Schmidt, Marie L. Schmidt +5 · 42 citations
Medicine · Neuroscience · #Parkinson's Disease Mechanisms and Treatments #Neurological diseases and metabolism #Nuclear Receptors and Signaling
paper · pdf · doi:10.1038/42166
Cited by
- Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
- HMGA1 deficiency: a pathogenic link between tau pathology and insulin resistance
- Changes in sensorimotor network dynamics in resting-state recordings in Parkinson’s disease
- Increased Serum Neurofilament Light Chain Levels in Parkinson's Disease Patients Carrying the p. A53T SNCA Mutation: Data from the Parkinson's Progression Markers Initiative Study
- Structural and thermodynamic classification of amyloid polymorphs
- How is the Amyloid Fold Built? Polymorphism and the Microscopic Mechanisms of Fibril Assembly
- Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis
- Large-scale visualization of α-synuclein oligomers in Parkinson’s disease brain tissue
- Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease
- Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease
- Transcriptional dysregulation in the cerebellum triggered by oligodendroglial α-synucleinopathy: insights from a transgenic mouse into the early disease mechanisms of MSA
- The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of α‐synuclein aggregates
- Disulfide engineering reveals unexpected pro- and anti-aggregation conformers of human α-synuclein
- Erythrocyte-derived extracellular vesicles transcytose across the blood-brain barrier to induce Parkinson’s disease-like neurodegeneration
- Co-expression-wide association studies link genetically regulated interactions with complex traits
- Copper Dyshomeostasis in Neurodegenerative Diseases—Therapeutic Implications
- Discordance of Dopaminergic Dysfunction and Subcortical Atrophy by α‐Synuclein Status in Sporadic and Genetic Parkinson's Disease
- Protection Against Cellular Toxicity from Rotenone Treatment by the Neuroprotective, Novel Multifunctional Antiparkinsonian Drug D-512
- Synaptic vesicle architecture modulates α-synuclein conformation and pathogenic transitions in Parkinson’s disease
- Engineering neuroimmune regulation: biomaterial and nanotechnology platforms for neuropathology diagnosis and targeted immunomodulation
- Uptake of alpha‐synuclein preformed fibrils is suppressed by inflammation and induces an aberrant phenotype in human microglia
- TREM2 Deficiency Aggravates NLRP3 Inflammasome Activation and Pyroptosis in MPTP-Induced Parkinson’s Disease Mice and LPS-Induced BV2 Cells
- Formation of seeding-competent α-synuclein aggregates in parkin-deficient iPSC-derived human neurons
- α‐Synuclein Pathology Spreads in a Midbrain–Hindbrain Assembloid Model
- Glycosphingolipids in neurodegeneration – Molecular mechanisms, cellular roles, and therapeutic perspectives
- Brain region-specific and systemic transcriptomic alterations in a human alpha-synuclein overexpressing rat model
- Biological Characterization of the Anti-ferroptotic Properties of a Novel Anti-Parkinsonian Iron (II) Selective Dopamine Agonist, D-583
- Diagnosing Synucleinopathies: Will Parkinson’s Disease or Dementia with Lewy Bodies Become ‘Biologically’ Defined?
- Stem cell treatments and Parkinson's disease: Science and misconceptions
- Autophagy–exosome crosstalk in neurodegeneration: Mechanisms and therapeutic opportunities
- Evaluating alpha-synuclein proteinopathy and consequences for birdsong in zebra finch basal ganglia area X
- Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission
- In vivo aggregation of presynaptic alpha-synuclein is not influenced by its phosphorylation at serine-129
- Pharmacological strategies for managing dementia with Lewy bodies: an expert review of symptom-targeted care
- H<scp>UMAN</scp> N<scp>EURODEGENERATIVE</scp> D<scp>ISEASE</scp> M<scp>ODELING</scp> U<scp>SING</scp> <i>D<scp>ROSOPHILA</scp></i>
- Diabetes mellitus, prediabetes and the risk of Parkinson’s disease: a systematic review and meta-analysis of 15 cohort studies with 29.9 million participants and 86,345 cases
- Mitochondrial dysfunction and mitophagy defects in LRRK2-R1441C Parkinson’s disease models
- Metabolic Rewiring by α-Synuclein Enables Mitohormetic Protection
- Ubiquitin signatures on aggregating proteins in neurodegeneration
- Mitochondrial dysfunction, iron accumulation, and ferroptosis in Parkinson’s disease
- Pathological roles of MAPK signaling pathways in human diseases
- Cell-based therapies for Parkinson disease—past insights and future potential